Pfizer won't get access to NEJM reviews

Listen to all the medical journals breathing a collective "Whew!" A federal judge in Illinois said "nay" to Pfizer's request for peer-review documents from the New England Journal of Medicine. The drugmaker wanted those confidential documents because it thought they might help defend it against Celebrex and Bextra lawsuits.

The request put journals on the defensive. NEJM argued that releasing the data would compromise its peer-review process, under which experts vet studies before they're published. The journal Science filed an affidavit supporting that contention; it stated that setting this precedent would open all peer reviews up to subpoena and undermine the entire process.

The court decided that the value of letting Pfizer have the data was outweighed by the damage it would cause to the journals. A similar suit is pending in Massachusetts.

- see the item at Pharmalot

Related Articles:
Regulators add warning to Bextra, allow new indication. Report
Pfizer wins round against Celebrex claims. Report
Pfizer gets some Celebrex relief. Report
FDA panel backs Celebrex for children. Report
Celebrex works against precancerous polyps. Report

Suggested Articles

Patients with epithelioid sarcoma previously had no targeted treatment options, but that'll change with Epizyme's approval for Tazverik.

With federal prosecutors laying waste to Insys' executive team, one big domino was still left to fall: Founder and former CEO John Kapoor.

Amgen buys out Astellas Japanese joint venture. Sun Piaoyang steps down as Hengrui chairman. Moderna-NIH and Inovio work on coronavirus vaccines.